Combination Therapy for Treatment of Muscle Loss Due to Obesity Treatments
AssigneeNorthstrive Biosciences, Inc.
InventorsJordan Robert Plews, Deniel Mero
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination therapy of an approved GLP-1 receptor agonist treatment and a microorganism transformed with a cell surface display vector operably linked with a gene encoding myostatin and activin A proteins for the treatment of muscle loss related to obesity. The microorganism may be formulated to include pharmaceutically viable excipients, such as antiadherents, binders, carriers, coatings, colorants, disintegrants, diluents, flavorings, glidants, lubricants, preservatives, sorbents, or vehicles.
Claims8
A combination therapy, comprising an approved GLP-1 receptor agonist treatment and a microorganism transformed with a cell surface display vector operably linked to a gene encoding myostatin and activin A proteins, wherein the combination therapy is used for the treatment of muscle loss related to obesity treatments.
Dependencies are inferred from the claim text.